Literature DB >> 30219743

NMOSD with anti-MOG antibodies following anti-TNFα therapy: A case report.

Emilie Lommers1, Frédérique Depierreux2, Isabelle Hansen3, Dominique Dive3, Pierre Maquet3.   

Abstract

Tumor necrosis factor α (TNFα) inhibitors are highly effective and a therapeutic choice for several inflammatory diseases. Their broad and long-term use is associated with a growing number of paradoxical autoimmune events including demyelinating lesions of the central nervous system (CNS). We report and discuss a case of neuromyelitis optica spectrum disorder (NMOSD) with positive myelin oligodendrocyte glycoprotein antibodies (MOG-IgG1) following anti-TNFα therapy for a pustular psoriasis.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Demyelinating lesions; MOG-IgG; NMOSD; TNFα blockers

Mesh：

Substances：

Year:  2018        PMID： 30219743     DOI： 10.1016/j.msard.2018.08.029

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


  5 in total

1.  Pathological findings in central nervous system demyelination associated with infliximab.

Authors:  Alicja Kalinowska-Lyszczarz; Mahboobeh Fereidan-Esfahani; Yong Guo; Claudia F Lucchinetti; W Oliver Tobin
Journal:  Mult Scler       Date:  2019-12-17       Impact factor: 6.312

Review 2.  Drug-related immune-mediated myelopathies.

Authors:  David Gritsch; Cristina Valencia-Sanchez
Journal:  Front Neurol       Date:  2022-09-29       Impact factor: 4.086

Review 3.  Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system.

Authors:  Elsa How Shing Koy; Pierre Labauge; Athan Baillet; Clément Prati; Hubert Marotte; Yves-Marie Pers
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-07-09       Impact factor: 5.346

4.  Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.

Authors:  Solène Dauby; Dominique Dive; Laurence Lutteri; Cécile Andris; Isabelle Hansen; Pierre Maquet; Emilie Lommers
Journal:  Acta Neurol Belg       Date:  2021-06-07       Impact factor: 2.396

5.  Intravenous Immunoglobulin in the Treatment of Adalimumab-associated Optic Neuritis.

Authors:  Naohiro Uchio; Daiki Yashita; Akihito Hao; Toshiyuki Takahashi; Hideyuki Matsumoto
Journal:  Intern Med       Date:  2021-08-06       Impact factor: 1.271
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.